Plus Therapeutics Inc (PSTV)
Summary
Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates
Plus Therapeutics (PSTV) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to a loss of $14 per share a year ago.
Plus Therapeutics (PSTV) Reports Break-Even Earnings for Q4
Plus Therapeutics (PSTV) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.67 per share a year ago.
Plus Therapeutics (PSTV) Reports Q3 Loss, Lags Revenue Estimates
Plus Therapeutics (PSTV) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.46 per share a year ago.
Plus Therapeutics Inc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Cynthia Schlanger Ashton Thomas Private Wealth, LLC | 996.52 | $12,763.43 | $5,411.1 | -$7,352.33 | -57.6% |
Plus Therapeutics Inc (PSTV) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Plus Therapeutics Inc ever had a stock split?
Plus Therapeutics Inc Profile
| Biotechnology Industry | Healthcare Sector | Marc H. Hedrick CEO | NASDAQ (CM) Exchange | 72941H806 CUSIP |
| US Country | 21 Employees | - Last Dividend | 2 Apr 2026 Last Split | 16 Nov 2000 IPO Date |
Overview
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company that is primarily engaged in the development, manufacture, and commercialization of novel treatments aimed at patients suffering from cancer. Initially founded in 1996 as Cytori Therapeutics, Inc., the company underwent a name change in July 2019 to better reflect its expanded focus on cancer therapies. Positioned at the forefront of radiotherapeutic innovation, Plus Therapeutics is headquartered in Austin, Texas, and is dedicated to providing advanced treatment options for a variety of cancers, with a particular emphasis on central nervous system cancers.
Products and Services
- Rhenium (186Re) obisbemeda
This patented radiotherapy drug candidate is at the center of the company's product pipeline. Designed specifically to target central nervous system cancers, rhenium (186Re) obisbemeda has shown potential in treating recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It represents Plus Therapeutics' commitment to addressing hard-to-treat cancers through innovative radiotherapeutic solutions.
- Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere
An advanced development geared towards the treatment of various solid organ cancers, this product aims at primary and secondary liver cancers through intra-arterial injection. The therapeutic leverages the unique properties of Rhenium-188 incorporated into nano-liposome particles, offering a novel approach for cancer treatment. It underscores the company’s focus on leveraging nanotechnology for enhancing drug delivery and efficacy.
Additionally, Plus Therapeutics has established strategic license agreements with NanoTx, Corp., and The University of Texas Health Science Center at San Antonio to bolster its research capabilities and facilitate the development of its therapeutic portfolio.
